Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
CNTB Total Non-current Liabilities
All obligations due after more than one year.
Connect Biopharma Holdings LimitedNASDAQ: CNTB
Total Non-current Liabilities · Q4 FY2025 · quarter ended Dec 2025
Total non-current liabilities falls 26.5% from a year ago
Total non-current liabilities stood at $482K at the end of Q4 FY2025, down 26.5% from a year earlier. Over 3 fiscal years it compounded at -18.7% a year.
Context
- Total non-current liabilities amounted to 0.9% of total assets at the end of Q4 FY2025, up 0.2 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -26.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 482K USD
- Year-over-year change
- -26.5%
- 4-year CAGR
- -12.2%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 482K | -26.5% |
| FY2024 | 2024-12-31 | 656K | +12.1% |
| FY2023 | 2023-12-31 | 585K | -34.8% |
| FY2022 | 2022-12-31 | 897K | +10.7% |
| FY2021 | 2021-12-31 | 810K | — |
Total Non-current Liabilities vs competitors
How CNTB compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -26.5% is the 8th highest of 9, against a peer median of +7.3%.
- Total non-current liabilities amounts to 0.9% of total assets for CNTB, versus a peer median of 5.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $238.06M USD | +11.1% | +23.3% | 98.4% | |
KLRSKalaris Therapeutics Inc | Mar 2026 | $33.17M USD | +3.4% | +5.3% | 30.2% |
| Mar 2026 | $11.61M USD | -11.2% | -9.2% | 5.1% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $7.23M USD | -29.7% | -68.3% | 6.8% |
IMAImageneBio Inc | Mar 2026 | $6.72M USD | +77.1% | +31.5% | 4.9% |
| Mar 2026 | $2.04M USD | -10.1% | -27.8% | 2.0% | |
| Mar 2026 | €609.25K EUR | +83.3% | -12.9% | 1.2% | |
| Dec 2025 | $482K USD | -26.5% | -18.7% | 0.9% | |
| Mar 2026 | $122.37K USD | +48.1% | — | 0.2% | |
| Peer median (excluding CNTB) | — | +7.3% | -9.2% | 5.0% | |
Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 267.72M | 79.01M | 105.66M | 78.23M | 38.35M |
| Short-term Investments | 0 | 73.41M | 12.64M | 15.48M | 6M |
| Net Receivables | 7.41M | 232K | 351K | 1.05M | 161K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 54K | 419K | 29K |
| Total Current Assets | 275.13M | 155.78M | 122.55M | 96.96M | 50.93M |
| Property, Plant & Equipment (Net) | 9.44M | 5.38M | 4.74M | 4.24M | 4.46M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 3.54M | 3.17M | 62K | 53K | 45K |
| Long-term Investments | 0 | 9.44M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.95M | 252K | 24K | 33K | 646K |
| Total Non-current Assets | 15.93M | 18.23M | 4.82M | 4.32M | 5.15M |
| Total Assets | 291.05M | 174.01M | 127.38M | 101.28M | 56.08M |
| Account Payables | 12.74M | 11.94M | 2.21M | 342K | 1.96M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 13.32M | 164K | 167K |
| Other Current Liabilities | 0 | 0 | 2.05M | 3.34M | 2.91M |
| Total Current Liabilities | 17.99M | 15.62M | 25.29M | 8.46M | 13.61M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 784K | 652K | 405K | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 632K | 114K |
| Total Non-current Liabilities | 810K | 897K | 585K | 656K | 482K |
| Total Liabilities | 18.8M | 16.52M | 25.88M | 9.12M | 14.1M |
| Common Stock | 10K | 10K | 10K | 10K | 10K |
| Retained Earnings | (361.75M) | (479.84M) | (329.73M) | (345.36M) | (400.84M) |
| Accumulated OCI | (4.03M) | (7.63M) | (1.01M) | (1.67M) | (1.19M) |
| Other Stockholders Equity | 9.57M | 16.47M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 272.26M | 157.49M | 101.5M | 92.17M | 41.98M |
| Total Debt | 125K | 431K | 465K | 178K | 690K |
| Net Debt | (267.59M) | (78.58M) | (105.2M) | (78.05M) | (37.66M) |
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.